Estimating The Potential Budget Impact Of Zelboraf (Vemurafenib) For Advanced Melanoma Treatment In Brazilian Private Health Care System

Abstract

DA Q3W has the potential to provide cost savings over EA QW in terms of annual average drug cost per patient ($654 savings), per member per year ($839 savings), and total cost per population ($1,471,340 savings). DA Q3W may offer a cost advantage over EA QW as it allows for synchronizing of anemia management with ongoing cancer treatments, which may reduce required patient visits and blood tests.